Get started
GENMAB ASGENMAB ASGENMAB AS

GENMAB AS

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

GMAB trade ideas

GMAB / GENMAB / Likely this is the scenarioThe last 10 Years give us an idea how this stock moves. Today i bough some expecting around 20% profit until End of July. I look at Seasonality / seasonal price tendencies and identified a good period to be long in that stock. I have confidence in that and my entry was the break of yesterday candle. Feel free to contact me for some chat. Leave a like or comment or both ;-) Trade what you see, trade what you understand and trade carefully and risk adjusted! Cheers!
NASDAQ:GMABLong
by ernstschwarz
Genmab opportunitysteamloss in the Genmab stock will likely fuel a new rush. 1) the 2 previous times times RSI has been below 30, it has resulted in strong returns. Will it happen a 3rd time? 2) The current strongly rising RSI will like make sure that the price will move and stay above the short term downward trend. 3) Opportunity for the price to move towards 2557 DKK. Yet be aware of potential strong resistance around 2364 DKK. 4) If this small up trend can offset the short term setback, 50/200 will likely trigger a new golden cross. Entered long in 2168 DKK
OMXCOP:GMABLong
by PersonalFinanceDude
GMAB Bull flagI've been reading through their studies to see what they're working on and what their proprietary info is being used for and it's actually impressive. Best part is that several of these studies are big on the public conscience, when one of these pops, I can easily see interest in this company peaking real quick. Partnerships with several major companies: BNTX, AMGN, JNJ, BMY. Note: BNTX is an absolutely incredible company, the stuff they're working out have potential to revolutionize medicine. Not overexagerating. FA: Net income, employees, etc all up each quarter. 13D: 3% held by major hedge funds. Analyst: Overweight by MS w/ PT upgrade to 41 TA: Bull flag. PT = 43$ at least.
NASDAQ:GMAB
by Dr_Tabb
Genmab $GMAB all time high after Q3 earnings beat #biotechNovember 4, 2020; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2020 Highlights Novartis granted U.S. FDA approval for Kesimpta® (ofatumumab) in relapsing multiple sclerosis Janssen and European Myeloma Network achieved positive topline results from Phase 3 APOLLO study of daratumumab in relapsed or refractory multiple myeloma Janssen was granted U.S. FDA approval for DARZALEX® (daratumumab) in combination with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma based on Phase 3 CANDOR study DARZALEX net sales increased 35% compared to the first nine months of 2019 to USD 2,937 million, resulting in royalty income of DKK 2,898 million for the first nine months of 2020 Genmab (GNMSF) commenced binding arbitration of two matters under daratumumab license agreement with Janssen Announcement of plan to transition Arzerra® (ofatumumab) to an oncology access program for chronic lymphocytic leukemia patients in the U.S. “Genmab continued to deliver on the promise of improving the lives of patients, with multiple regulatory milestones for Genmab-created products under development by our partners, including the exciting U.S. FDA’s approval of Kesimpta and the 8th U.S. FDA approval for DARZALEX,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “During the first nine months of 2020, with our solid financial footing Genmab has continued its focused investment in advancing its proprietary antibody product pipeline and building its capabilities as we evolve into a fully integrated biotech.” Financial Performance First Nine Months of 2020 Revenue was DKK 8,067 million in the first nine months of 2020 compared to DKK 2,405 million in the first nine months of 2019. The increase of DKK 5,662 million, or 235%, was primarily driven by the upfront payment from AbbVie pursuant to our new collaboration announced in June and higher DARZALEX royalties. Net sales of DARZALEX by Janssen Biotech Inc. (Janssen) were USD 2,937 million in the first nine months of 2020 compared to USD 2,168 million in the first nine months of 2019, an increase of USD 769 million, or 35%. Operating expenses were DKK 2,641 million in the first nine months of 2020 compared to DKK 1,943 million in the first nine months of 2019. The increase of DKK 698 million, or 36%, was driven by the advancement of epcoritamab (DuoBody®-CD3xCD20) and DuoBody-PD-L1x4-1BB, additional investments in our product pipeline, and the increase in new employees to support the expansion of our product pipeline. Operating income was DKK 5,426 million in the first nine months of 2020 compared to DKK 462 million in the first nine months of 2019. The increase of DKK 4,964 million was driven by higher revenue, which was partly offset by increased operating expenses. Outlook Genmab is maintaining its 2020 financial guidance published on August 20, 2020.
OMXCOP:GMABLong
by savepiginvest